Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 265 (LINC00265) is a human long non-coding RNA gene that does not encode a protein but may regulate the transcription of genes nearby or at distant loci[3][5][6]. LINC00265 is upregulated in various cancers, including hepatocellular carcinoma, where it promotes malignant cell behaviors by interacting with E2F1 transcription factor and enhancing transcription of cyclin-dependent kinase 2 (CDK2)[6]. LINC00265 may serve as a prognostic biomarker for certain malignancies but is not a conventional therapeutic target such as a receptor, enzyme, or transporter[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 265 (LINC00265).